Key Points
- Major shareholder Financial Lp Hrt sold 42,411 Profusa shares at an average price of $0.89, totaling $37,745.79. The sale reduced its holdings by 36.37% to 74,198 shares.
- Profusa’s stock opened at $0.90, with a market capitalization of approximately $171,000, and is scheduled for a 1-for-4 reverse stock split after the close on August 16.
- Analyst sentiment remains negative: Profusa has a consensus rating of “Sell”, while the company continues developing implantable biosensors for continuous physiological monitoring.
Profusa, Inc. (NASDAQ:PFSA - Get Free Report) major shareholder Financial Lp Hrt sold 42,411 shares of Profusa stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $0.89, for a total transaction of $37,745.79. Following the completion of the transaction, the insider directly owned 74,198 shares in the company, valued at $66,036.22. This represents a 36.37% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.
Financial Lp Hrt also recently made the following trade(s):
- On Wednesday, August 12th, Financial Lp Hrt bought 5,585 shares of Profusa stock. The shares were acquired at an average cost of $0.96 per share, with a total value of $5,361.60.
- On Tuesday, August 4th, Financial Lp Hrt bought 1,368 shares of Profusa stock. The shares were acquired at an average price of $0.95 per share, with a total value of $1,299.60.
- On Monday, August 3rd, Financial Lp Hrt bought 14,556 shares of Profusa stock. The shares were acquired at an average price of $0.96 per share, with a total value of $13,973.76.
- On Wednesday, July 29th, Financial Lp Hrt purchased 1,310 shares of Profusa stock. The stock was acquired at an average price of $1.01 per share, for a total transaction of $1,323.10.
Profusa Stock Performance
NASDAQ PFSA opened at $0.90 on Friday. The stock has a market capitalization of $170,962.00, a P/E ratio of -0.00 and a beta of 0.52. Profusa, Inc. has a 1 year low of $0.81 and a 1 year high of $1,297.50. The business's fifty day moving average is $2.73 and its two-hundred day moving average is $24.89.
Profusa's stock is scheduled to reverse split on Monday, August 17th. The 1-4 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, August 16th.
Analyst Ratings Changes
A number of equities analysts recently weighed in on PFSA shares. Wall Street Zen upgraded Profusa from a "strong sell" rating to a "sell" rating in a research report on Saturday, April 18th. Weiss Ratings restated a "sell (e+)" rating on shares of Profusa in a report on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Sell".
Check Out Our Latest Research Report on Profusa
Profusa Company Profile
(
Get Free Report)
Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.
The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
